Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.3% - Should You Sell?

Key Points

• Structure Therapeutics Inc. stock (NASDAQ: GPCR) fell 4.3% to $26.81, with trading volume significantly down 88% from the average session.
• Analysts have a consensus rating of "Buy" for Structure Therapeutics, with a target price averaging $68.67, though recent ratings adjustments vary widely.
• The company reported earnings per share of ($0.36), missing the consensus estimate, and anticipates posting an EPS of (0.82) for the current year.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) fell 4.3% on Wednesday . The stock traded as low as $26.79 and last traded at $26.81. 108,928 shares were traded during trading, a decline of 88% from the average session volume of 909,202 shares. The stock had previously closed at $28.00.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a research note on Monday, September 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Guggenheim dropped their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. HC Wainwright decreased their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $68.67.

Structure Therapeutics Stock Performance

The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -24.96 and a beta of -1.88. The firm's 50-day moving average price is $20.09 and its two-hundred day moving average price is $20.85.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GPCR. Pacific Heights Asset Management LLC bought a new position in shares of Structure Therapeutics in the second quarter valued at about $9,540,000. Orbimed Advisors LLC raised its stake in shares of Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company's stock worth $24,873,000 after acquiring an additional 397,272 shares during the last quarter. Readystate Asset Management LP lifted its position in shares of Structure Therapeutics by 129.9% during the first quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock worth $8,330,000 after purchasing an additional 271,899 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Structure Therapeutics by 130.3% during the first quarter. Handelsbanken Fonder AB now owns 380,000 shares of the company's stock valued at $6,578,000 after purchasing an additional 215,000 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $3,480,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.